Respiree develops a monitoring platform called 1Bio™ that integrates FDA‑cleared wearable sensors, artificial intelligence, and electronic health record connectivity to track the condition of patients with cardio‑respiratory diseases. Its system is designed to identify early signs of clinical deterioration to enable clinicians to intervene before critical events occur, with deployments reported in both hospital and home care settings. The company says its technology contributes to reducing hospital admissions and ICU transfers. Respiree is based at the Texas Medical Center Innovation campus in Houston and benefits from the TMC HealthTech Accelerator’s clinical, regulatory, and market-access support. Current company plans, supported by the Series A proceeds, focus on U.S. commercial expansion, strengthening the Houston headquarters, and advancing the proprietary platform’s development.

Total raised

$12M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2026